(Z)-2-[(4-fluorophenyl)-methylene]-4-methyl-3-oxopentanoic acid ethyl ester | 123477-31-6

• 分子结构分类: 有机化合物 - 苯丙烷和聚酮 - 肉桂酸及其衍生物
• 英文名称: (Z)-2-[(4-fluorophenyl)-methylene]-4-methyl-3-oxopentanoic acid ethyl ester
• 英文别名: (Z)-2-<(4-fluorophenyl)methylene>-4-methyl-3-oxopentanoic acid ethyl ester；2-[(4-Fluorophenyl)methylene]-4-methyl-3-oxopentanoic acid,ethyl ester；ethyl (Z)-2-[(4'-fluorophenyl)methylene]-4-methyl-3-oxopentanoate；2-[(4-Fluorophenyl)methylene]-4-methyl-3-oxopentanoic acid, ethyl ester；(Z)-2-[(4-fluorophenyl)methylene]-4-methyl-3-oxopentanoic acid ethyl ester；Ethyl 2-(4-fluorobenzylidene)-4-methyl-3-oxopentanoate；ethyl (2Z)-2-[(4-fluorophenyl)methylidene]-4-methyl-3-oxopentanoate
• CAS: 123477-31-6
• 化学式: C₁₅H₁₇FO₃
• 分子量: 264.297
• InChiKey: LOQOYHQUQSXJCE-LCYFTJDESA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.6
• 重原子数：
  19
• 可旋转键数：
  6
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  43.4
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  (Z)-2-[(4-fluorophenyl)-methylene]-4-methyl-3-oxopentanoic acid ethyl ester 、 ethyl (2E)-3-amino-4-methyl-2-pentenoate 以23%的产率得到
  参考文献：
  名称：

  ANGERBAUER, ROLF;FEY, PETER;HUBSCH, WALTER;PHILIPPS, THOMAS;BISCHOFF, HIL+

  摘要：

  DOI：
• 作为产物：
  描述：

  对氟苯甲醛 、 异丁酰乙酸乙酯 在 溶剂黄146 作用下， 以 苯 为溶剂， 以83%的产率得到(Z)-2-[(4-fluorophenyl)-methylene]-4-methyl-3-oxopentanoic acid ethyl ester
  参考文献：
  名称：

  Pyridine anchors for HMG-CoA reductase inhibitors

  摘要：

  提供了一些有用的化合物，这些化合物可作为胆固醇生物合成抑制剂，因此可作为降胆固醇药物。这些化合物具有喹啉或吡啶锚点，通过连接剂连接到结合域侧链，这些化合物抑制酶3-羟基-3-甲基戊二酰辅酶A还原酶。

  公开号：

  US05506219A1

文献信息

• HMG-CoA reductase inhibitors
  申请人：Stein Philip D.

  公开号：US20070249583A1

  公开（公告）日：2007-10-25

  Compounds are provided of the following structure are HMG CoA reductase inhibitors and thus are active in inhibiting cholesterol biosynthesis, modulating blood serum lipids, for example, lowering LDL cholesterol and/or increasing HDL cholesterol, and treating hyperlipidemia and dyslipidemia, hypercholesterolemia, hypertriglyceridemia and atherosclerosis wherein A is chosen from B is chosen from wherein the variables R 1 to R 7 , m, n, are as defined herein. A method for treating the above diseases employing the above compounds is also provided.

  提供以下结构的化合物是HMG CoA还原酶抑制剂，因此在抑制胆固醇生物合成、调节血清脂质，例如降低LDL胆固醇和/或增加HDL胆固醇，以及治疗高脂蛋白血症和血脂异常、高胆固醇血症、高甘油三酯血症和动脉粥样硬化方面具有活性。 其中A选择自 B选择自 其中变量R1至R7，m，n， 如本文所定义。 还提供了一种利用上述化合物治疗上述疾病的方法。
• Phosphorus-containing inhibitors of HMG-CoA reductase. 2. Synthesis and biological activities of a series of substituted pyridines containing a hydroxyphosphinyl moiety
  作者：Jeffrey A. Robl、Laurelee A. Duncan、Jelka Pluscec、Donald S. Karanewsky、Eric M. Gordon、Carl P. Ciosek、Lois C. Rich、Viviane C. Dehmel、Dorothy A. Slusarchyk

  DOI：10.1021/jm00113a019

  日期：1991.9

  A series of 2,3,4,(5),6-substituted pyridines containing a hydroxyphosphinyl functionally have been prepared and were evaluated for their ability to inhibit the enzyme HMG-CoA reductase. Systematic substitution of both R1-R4 and X-Y led to compounds of type 3-6 with in vitro potency greater than that of mevinolin (Na salt).

  已经制备了一系列的2,3,4，（5），6-取代的功能上含有羟基膦酰基的吡啶，并对其抑制酶HMG-CoA还原酶的能力进行了评估。R1-R4和XY的系统取代产生了3-6型化合物，其体外效能大于mevinolin（Na盐）。
• PROCESS FOR PREPARING ROSUVASTATIN CALCIUM
  申请人：Dandala Ramesh

  公开号：US20100048899A1

  公开（公告）日：2010-02-25

  The present invention relates to an improved process for preparing Rosuvastatin calcium of Formula I.

  本发明涉及一种改进的制备化学式I的罗伴他汀钙的方法。
• Process for the preparation of key intermediates for the synthesis of statins or pharmaceutically acceptable salts thereof
  申请人：LEK Pharmaceuticals d.d.

  公开号：EP2423195A1

  公开（公告）日：2012-02-29

  The invention relates to commercially viable process for the synthesis of key intermediates for the preparation of statins, in particular Rosuvastatin and Pitavastatin or respective pharmaceutically acceptable salts thereof. A new simple and short synthetic route for key intermediates is presented which benefits from the use of cheap and readily available starting materials, by which the conventionally most frequently used DIBAL-H as reducing agent can be avoided.

  该发明涉及一种用于合成他汀类药物的关键中间体的商业可行过程，特别是Rosuvastatin和Pitavastatin，或其相应的药用盐。提供了一种新的简单和短的关键中间体合成路线，利用廉价且易获得的起始原料，避免了传统上最常用的还原剂DIBAL-H的使用。
• Pyrimidinyl-substituted hydroxyacids, lactones and esters and pharmaceutical compositions containing them
  申请人：SANDOZ AG

  公开号：EP0367895A1

  公开（公告）日：1990-05-16

  Compounds of formula I wherein R¹, R², Q, X and Y have various significances, in free acid form, or in the form of an ester or δ-lactone thereof, or in salt form as appropriate, are described. They are indicated for use as hypolipoproteinemic and anti-atherosclerotic agents. They may be obtained by reduction, hydrolysis, deprotection or oxidation of appropriate starting compounds, and variously interconverted by e.g. hydrolysis, salt formation, esterification and/or lactonisation.

  式I中的化合物，其中R¹、R²、Q、X和Y具有不同的含义，在游离酸形式中，或者以其酯或δ-内酯的形式，或者以盐的形式描述。它们被指定用作降低脂蛋白和抗动脉粥样硬化药物。它们可以通过还原、水解、去保护或氧化适当的起始化合物获得，并通过水解、盐形成、酯化和/或内酯化等方法进行各种互变。